Press Releases GeNeuro SA

Equities

GNRO

CH0308403085

Market Closed - Euronext Paris Other stock markets 10:00:15 2024-05-07 am EDT			5-day change	1st Jan Change
1.475 ^EUR	+1.03%		+0.68%	+35.32%

Mar. 20	Geneuro SA Announces Appointments of Board of Directors	CI
Feb. 02	GeNeuro: share price falls after private placement	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GeNeuro Publishes its 2024 Universal Registration Document	May. 02	BU
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update	Apr. 30	BU
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting	Mar. 20	BU
GeNeuro - Independent Data Monitoring Committee recommends continuing the trial evaluating temelimab in Long COVID without any modifications	Dec. 12	AQ
GeNeuro : Investor Presentation October 2023	23-10-20	PU
GeNeuro : Half yearly financial reports and audit reports/limited reviews / Half yearly financial report	23-10-06	PU
GeNeuro Reports 2023 Half-Year Results and Provides Corporate Update	23-10-03	AQ
GeNeuro - New study published in PNAS further substantiates the neuropathogenic role of the HERV-W protein in MS	23-09-28	AQ
GeNeuro, financial information for the second quarter 2023	23-07-26	AQ
GeNeuro : Result of votes at Annual General Meeting of Shareholders of 14 June 2023	23-06-22	PU
GeNeuro Announces Approval of all Resolutions Proposed at 2023 Annual General Meeting	23-06-16	AQ
GeNeuro : Inside Information / Other news releases	23-05-03	PU
GeNeuro : 2022 Universal Registration Document	23-04-30	PU
GeNeuro : 2022 Universal Registration Document	23-04-28	PU
GeNeuro : Document Universel d'Enregistrement 2022 (en anglais)	23-04-27	PU
GeNeuro, financial information for the first quarter 2023	23-04-14	AQ
GeNeuro Reports 2022 Full-Year Results and Provides Corporate Update	23-04-06	AQ
The EIB and GeNeuro sign a EUR 25 million credit line backed by InvestEU to support clinical developments against long-COVID	23-03-08	AQ
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab	22-11-17	AQ
The Karolinska Institutet's Academic Specialist Center to Present Results of GeNeuro's ProTEct-MS Phase 2 Study of Temelimab at ECTRIMS 2022	22-10-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases GeNeuro SA

Equities

GNRO

CH0308403085

Press Releases

Filters